Table 6.

Change from baseline in urine ketone levels in the pooled comparative ipragliflozin studies

Time point	Ipragliflozin 50 mg (N = 1209)		Placebo (N = 796)
	1+ n (%)a	3+ n (%)b	1+ n (%)a	3+ n (%)b
Baseline	22/1206 (1.8)	4/1206 (0.3)	15/795 (1.9)	1/795 (0.1)
Week 2	72/945 (7.6)	2/945 (0.2)	11/600 (1.8)	0
Week 12	61/1140 (5.4)	7/1140 (0.6)	12/702 (1.7)	0
End of treatment period	58/1202 (4.8)	6/1202 (0.5)	9/792 (1.1)	0

^aNumber of patients with 1+ or higher (2+, 3+ or 4+)/number of patients with available laboratory values at each time point (%)

^bNumber of patients with 3+ or 4+/number of patients with available laboratory values at each time point (%)